This inventor holds 4 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Genmab A+s, Biontech Se. Active years: 2014-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 107 
2 out of 76 
Years Active: 2014-2025
Title: Esther Cornelia Wilhelmina Breij: Pioneering Innovator in Immunotherapy
Introduction
Esther Cornelia Wilhelmina Breij is a distinguished inventor based in Utrecht, Netherlands. With a remarkable portfolio of three patents, he has significantly contributed to the field of immunotherapy, particularly focusing on the development of monoclonal antibodies. His innovative work aims to address critical medical challenges, particularly in cancer treatment.
Latest Patents
Breij's latest patent involves monoclonal antibodies directed against the programmed death-1 (PD-1) protein and their applications in medicine. This invention pertains to antibodies designed to bind to the immune checkpoint protein PD-1, with modifications in the Fc region that reduce or eliminate Fc-mediated effector functions. This advancement offers new avenues for immunotherapy, specifically in treating cancers by inducing immune responses in subjects through the administration of these antibodies or their encoding nucleic acids.
Another significant patent he holds is for isolated monoclonal antibodies against CD32b. This invention includes antibody-based compositions and molecules that can bind to human CD32b, along with pharmaceutical compositions and therapeutic methods utilizing these antibodies. These innovations have the potential to enhance both diagnostic and therapeutic approaches in healthcare.
Career Highlights
Throughout his career, Breij has made substantial contributions while working with notable companies in the biotechnology sector, such as Genmab and BioNTech SE. His expertise in developing advanced therapeutic solutions has established him as a key figure in the field.
Collaborations
Breij has collaborated with prominent researchers such as Aran Frank Labrijn and Edward Norbert Van Den Brink. These collaborations have further enriched his innovative endeavors, allowing for the cross-pollination of ideas and advancements in antibody technology.
Conclusion
Esther Cornelia Wilhelmina Breij's work exemplifies the transformative power of innovation in immunotherapy. With his pioneering patents and contributions to the scientific community, Breij continues to pave the way for advancements in cancer treatment, showcasing the vital role of inventors in the field of medicine. His dedication and expertise not only enhance therapeutic options but also hold promise for improving patient outcomes in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile